Ozempic vs. Mounjaro
Ozempic and Mounjaro differ in scope and efficacy. Ozempic is a GLP-1 receptor agonist for type 2 diabetes and reducing cardiovascular risks, while Mounjaro, a dual GIP and GLP-1 agonist, focuses on type 2 diabetes with superior HbA1c reductions. Both are used off-label for weight management, with Mounjaro showing greater weight loss potential. Common side effects, including nausea, have some overlap, though Mounjaro has a higher thyroid tumor risk. Mounjaro averages $1,135/month, higher than Ozempic’s $875/month. Neither faces current shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions